Biotech Investment Analyst — Drug Asset & Company Assessment
About this role
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales. Responsibilities - Create and critique rubrics that analyze commercial drugs and drug-development programs - Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers - Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions - Apply your assessment across the pilot's set of companies (~5–10) Requirements - US-based biotech / healthcare investment analyst with a specialist-fund background - Familiarity with biotech/pharma development programs - Able to assess a drug asset and the company behind it end-to-end - 5+ years evaluating biotech/pharma companies or assets Engagement Details - Duration: Approximately 10–20 hours over a 1–2 week pilot - Remote — US-based Why Participate - Help improve expert AI evaluation of drugs and drug-development programs - Recurring engagement for strong contributors
Application listings
Choose a source listing and check its country requirements.